Apremilast in psoriatic disease: therapeutic outcomes and cardiometabolic trajectories from a multicenter real-world study

Clicks: 4
ID: 337544
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #73 of 76 articles by views in Rheumatology Advances in Practice

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives To evaluate real-world effectiveness, safety, drug retention, and cardiometabolic effects of apremilast (APR) in psoriatic disease (PD). Methods This multicenter retrospective study included adults with psoriatic arthritis (PsA) or psoriasis (PsO) treated with APR. Disease activity and cardiometabolic parameters were assessed at baseline and at approximately 3, 6 and 12 months using mixed linear models. Adverse events (AEs), discontinuations, and drug retention rates (DRRs) up to 48 months were analyzed using Kaplan–Meier methods. Results 145 patients (mean age 66.5 years; 60.7% female sex) were included, 56 (38.6%) with PsO and 89 (61.4%) with PsA. The cohort had a high comorbidity burden, including malignancy in 91 patients (62.8%). Over 12 months, median Disease Activity in PsA decreased from 13.1 (IQR 13.3) to 6.0 (IQR 8.9)(p = 0.015), PsO Area and Severity Index from 8.0 (7.0) to 2.0 (IQR 3.0)(p ≤ 0.001), and pain Visual Analogue Scale from 6.0 (IQR 3.0) to 4.0 (IQR 3.0)(p < 0.001). Median BMI decreased from 27.0 (IQR 5.9) to 25.4 (IQR 6.0)(p = 0.003). Improvements were observed in total cholesterol (p < 0.001), HDL-C (p = 0.003), and triglycerides (p = 0.023), but not LDL-C (p = 0.087) in patients with untreated dyslipidemia. DRRs were 82.9% at 6 months, 65.5% at 12 months, 60.4% at 24 months, and 47.9% at 48 months. Lower DRRs were observed in patients with scalp or inverse PsO (p = 0.006 and p = 0.003). The most frequent AE was diarrhea (27, 18.6%). Conclusion APR appears to be a valid option for selected patients with PD when comorbidities and cardiometabolic risk influence treatment choice.
Reference Key
openalex_W7224103889 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Riccardo Terribili, Emanuele Trovato, Carla Gaggiano, Antonella Di Cesare, Martina Dragotto, Elia Rosi, Gemma Lepri, Maurizio Benucci, Federica Ricceri, Andrea Delle Sedie, Caterina Baldi, Pietro Rubegni, Bruno Frediani, Serena Guiducci, Francesca Prignano, Stefano Gentileschi
Journal Rheumatology Advances in Practice
Year 2026
DOI
10.1093/rap/rkag134
URL
https://doi.org/10.1093/rap/rkag134
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.